TAVR – Page 2 – Medxy AI

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

By MedXY 09/06/2025

The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.

Cardiology Clinical Updates news Specialties

Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions

By MedXY 08/17/2025

Underexpansion of the ACURATE neo2 valve during TAVR is linked to increased risk of death, stroke, and rehospitalization at one year, suggesting that achieving optimal valve expansion may improve patient outcomes.

Cardiology news Specialties

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY 08/17/2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concentrations.